Dergiler / Marmara Medical Journal / 2026 / Volume: 39 Issue: 3

Cutaneous flagellate hyperpigmentation with bleomycin in testicular germ cell malignancy: Case report

Sayfa
—
Yayın Tarihi
2026-10-28
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Awareness of this condition is essential to prevent misdiagnosis and unnecessary modification of chemotherapy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Bleomycin is an integral component of chemotherapy regimens for testicular germ cell tumors.
📊
Temel Bulgular & Veri:A 21-year-old male undergoing treatment for testicular germ cell tumor received bleomycin (30 U diluted in 500 mL normal saline, infused intravenously over 1 hour on days 1, 8, and 15; Cycle 2).
💡
Sonuç & Katkı:Awareness of this condition is essential to prevent misdiagnosis and unnecessary modification of chemotherapy.
🔬Tür:Case Report
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Antineoplastic Agents · Flagellate erythema · Germ cell tumor

Abstract

Bleomycin is an integral component of chemotherapy regimens for testicular germ cell tumors. While effective, it can produce characteristic cutaneous adverse reactions. Among these, flagellate dermatosis is rare but distinctive, and timely recognition is important to avoid misdiagnosis and unnecessary discontinuation of therapy. A 21-year-old male undergoing treatment for testicular germ cell tumor received bleomycin (30 U diluted in 500 mL normal saline, infused intravenously over 1 hour on days 1, 8, and 15; Cycle 2). Within 8–10 hours following infusion, he developed multiple linear, whip-like erythematous streaks that gradually evolved into hyperpigmented macules and patches. The distribution involved the trunk, extremities, neck, palms, soles, and scalp. The lesions were pruritic but not painful, and there was no mucosal or systemic involvement. The cumulative dose of bleomycin at the time of onset was approximately 60 units. The patient was treated with oral antihistamines and topical mometasone furoate 0.1% cream, resulting in significant improvement in pruritus. Over the following months, the erythematous changes subsided, and the residual pigmentation gradually faded and resolved completely. Bleomycin-induced flagellate hyperpigmentation is a benign, self-limiting cutaneous reaction. Management is primarily supportive, including emollients and symptomatic therapy. It is important to distinguish this condition from dermatitis artefacta and dermographism. As the reaction is primarily cosmetic, discontinuation of bleomycin is rarely required unless pigmentation is extensive or distressing. In contrast to typical presentations, this case demonstrated an unusually early onset and atypical distribution involving the palms, soles, and scalp. Flagellate dermatosis is an uncommon but characteristic cutaneous manifestation of bleomycin therapy. Early recognition, appropriate patient counselling, and supportive care allow continuation of chemotherapy without interruption. Awareness of this condition is essential to prevent misdiagnosis and unnecessary modification of chemotherapy.

🔖

Bu Makaleye Atıf Yap

Jha, A. N., Alam, R., Tyagi, S., Sharma, S., Gupta, R., Mittal, P., Goel, S., Gupta, A. K. (2026). Cutaneous flagellate hyperpigmentation with bleomycin in testicular germ cell malignancy: Case report. Marmara Medical Journal, Volume: 39 Issue: 3. https://doi.org/10.5472/marumj.2071807

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (22)

  1. Karamanolis NN, Kounatidis D, Vallianou NG, et al. Unraveling the anti-cancer mechanisms of antibiotics: Current insights, controversies, and future perspectives. Antibiotics (Basel) 2024;14:1-22.
  2. Froudarakis M, Hatzimichael E, Kyriazopoulou L, et al. Revisiting bleomycin from pathophysiology to safe clinical use. Crit Rev Oncol Hematol 2013;87:90-100. doi:10.1016/j.critrevonc.2012.12.003
  3. Ayoubifar M, Abedi F, Moeini Nodeh M, Arasteh O. Pharmacological approach for prevention of bleomycin-induced lung injury. J Pharm Care 2023; 11: 32-9. doi: 10.18502/jpc.v11i1.12638
  4. Marjoncu D, Holman K. The impact of bleomycin test doses on the development of acute hypersensitivity reactions. Support Care Cancer 2025;33:840-8. doi: 10.1007/s00520-025-09902-y
  5. Jiang Y, Huang Z, Zhou T, et al. Mitochondria-target ubiquinone attenuates bleomycin-induced pulmonary fibrosis. Front Pharmacol 2025;16(1661644) 1-12. doi: 10.3389/fphar.2025.1661644
  6. Arinami K, Kawaguchi G, Ito K, et al. A case of complete remission achieved through stereotactic radiotherapy for isolated bone metastasis following four courses of bleomycin, etoposide, and cisplatin chemotherapy for testicular cancer. IJU Case Rep 2025;8:508-12. doi: 10.1002/iju5.70080
  7. Burgy O, Wettstein G, Bellaye PS, et al. Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity. Sci Transl Med 2016; 326: 326ra20. doi: 10.1126/scitranslmed.aad7785.
  8. Brnić S, Špiljak B, Zanze L, Barac E, Likić R, Lugović-Mihić L. Treatment strategies for cutaneous and oral mucosal side effects of oncological treatment in breast cancer: A comprehensive review. Biomedicines 2025;30:1901-34. doi: 10.3390/biomedicines13081901
  9. C. A. Naranjo, U. Busto, E. M. Sellers, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;239-45. doi: 10.1038/clpt.1981.154.
  10. Biswas A, Julka PK. Bleomycin induced flagellate erythema in a patient with thalamic mixed germ cell tumour: Report of a rare adverse effect. J Egypt Natl Canc Inst 2016;28:129-32. doi: 10.1016/j.jnci.2016.04.002
  11. Changal KH, Raina H, Changal QH, Raina M. Bleomycin-induced flagellate erythema: A rare and unique drug rash. West Indian Med J 2014;63:807-9. doi: 10.7727/wimj.2014.060
  12. Grošelj A, Jamšek Č, Kranjc Brezar S, et al. Long-term outcomes of reduced-dose bleomycin in electrochemotherapy for basal cell carcinoma in elderly patients. Sci Rep 2025;15:13688-13795. doi: 10.1038/s41598-025-93104-3
  13. Moulin G, Fiere B, Beyvin A. Cutaneous pigmentation caused by bleomycin. Bull Soc Fr Dermatol Syphiligr 1970;77:293-6.
  14. Lazo JS, Humphreys CJ. Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci U S A 1983;80:3064-8. doi: 10.1073/pnas.80.10.3064
  15. Fyfe AJ, McKay P. Toxicities associated with bleomycin. J R Coll Physicians Edinb 2010;40:213-5. doi: 10.4997/jrcpe.2010.306
  16. Dantzig PI. Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol 1974;110:393-406.
  17. Ziemer M, Goetze S, Juhasz K. Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy. Am J Clin Dermatol 2011;12:68-76. doi: 10.2165/11537080-000000000-00000.
  18. Chen YB, Rahemtullah A, Breeden E, Hochberg EP. Bleomycin-induced flagellate erythema. J Clin Oncol 2007;25:898-900. doi: 10.1200/JCO.2006.09.7691
  19. Rubeiz NG, Salem Z, Dibbs R. Bleomycin-induced urticarial flagellate drug hypersensitivity reaction. Int J Dermatol 1999;38:140-1. 10.1046/j.1365-4362.1999.00344.x.
  20. Miori L, Vignini M, Rabbiosi G. Flagellate dermatitis after bleomycin: a histological and immunohistochemical study. Am J Dermatopathol 1990;12:598-602. doi:10.1097/00000372-199012000-00011
  21. Fernandez-Obregon AC, Hogan KP, Bibro MK. Flagellate pigmentation from intrapleural bleomycin: a light microscopy and electron microscopy study. J Am Acad Dermatol 1985;13:464-8 doi: 10.1016/s0190-9622(85)70190-9
  22. Al-Khenaizan S, Al-Berouti B. Flagellate pigmentation: a unique adverse effect of bleomycin therapy. Eur J Dermatol 2011;21:146-152. doi: 10.1684/ejd.2011.1213 Yamamoto T, Nishioka K. Flagellate erythema. Int J Dermatol 2006;45:627-31. doi: 10.1111/j.1365-4632.2005.02647.x